Neurocognitive function and health-related quality of life in a nationwide cohort of long-term childhood brain tumor survivors.
childhood brain tumor survivors
health-related quality of life
neurocognition
symptom burden
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Childhood brain tumor survivors are at high risk of late effects, especially neurocognitive impairment. Limited data are available examining neurocognitive function and associations with quality of life (QoL) in childhood brain tumor survivors. Our aim was to examine neurocognitive function in childhood brain tumor survivors, and associations with QoL and symptom burden. Five-year survivors of brain tumors over the age of 15 were identified in the Danish Childhood Cancer Registry ( In total, 170 survivors participated (40.2% participation rate). Sixty-six percent of the survivors who completed neurocognitive tests ( In this study, a majority of the childhood brain tumor survivors experienced neurocognitive impairment, reduced QoL, and high symptom burden. Although not associated with each other, it is apparent that childhood brain tumor survivors experience not only neurocognitive dysfunction but may also experience QoL impairments and significant symptom burden.
Sections du résumé
Background
UNASSIGNED
Childhood brain tumor survivors are at high risk of late effects, especially neurocognitive impairment. Limited data are available examining neurocognitive function and associations with quality of life (QoL) in childhood brain tumor survivors. Our aim was to examine neurocognitive function in childhood brain tumor survivors, and associations with QoL and symptom burden.
Methods
UNASSIGNED
Five-year survivors of brain tumors over the age of 15 were identified in the Danish Childhood Cancer Registry (
Results
UNASSIGNED
In total, 170 survivors participated (40.2% participation rate). Sixty-six percent of the survivors who completed neurocognitive tests (
Conclusions
UNASSIGNED
In this study, a majority of the childhood brain tumor survivors experienced neurocognitive impairment, reduced QoL, and high symptom burden. Although not associated with each other, it is apparent that childhood brain tumor survivors experience not only neurocognitive dysfunction but may also experience QoL impairments and significant symptom burden.
Identifiants
pubmed: 36970169
doi: 10.1093/nop/npac085
pii: npac085
pmc: PMC10037941
doi:
Types de publication
Journal Article
Langues
eng
Pagination
140-151Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuroimage Clin. 2015 Jan 13;7:325-35
pubmed: 25610797
Dev Med Child Neurol. 2013 May;55(5):408-17
pubmed: 23157447
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Oncol. 2021 Jun 1;39(16):1824-1832
pubmed: 33886353
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e363-9
pubmed: 22867897
Neurooncol Pract. 2017 Sep;4(3):161-170
pubmed: 31385949
Cancers (Basel). 2021 Jul 15;13(14):
pubmed: 34298751
J Clin Oncol. 2016 Apr 20;34(12):1358-67
pubmed: 26834063
JAMA. 2007 Jun 27;297(24):2705-15
pubmed: 17595271
Clin Epidemiol. 2016 Oct 25;8:461-464
pubmed: 27822085
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Child Neuropsychol. 2013;19(4):370-84
pubmed: 22420326
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Pediatr Blood Cancer. 2022 Feb;69(2):e29491
pubmed: 34842359
J Pediatr Oncol Nurs. 2014 Mar-Apr;31(2):65-77
pubmed: 24608699
J Clin Oncol. 2021 Jun 1;39(16):1718-1726
pubmed: 33886348
J Clin Oncol. 1998 May;16(5):1723-8
pubmed: 9586884
Psychooncology. 2013 Sep;22(9):1979-86
pubmed: 23447439
Psychooncology. 2008 Nov;17(11):1157-61
pubmed: 18636431
Psychooncology. 2020 Aug;29(8):1355-1362
pubmed: 32597001
Psychooncology. 2013 Aug;22(8):1731-7
pubmed: 23059621
Pediatr Blood Cancer. 2021 Aug;68(8):e29130
pubmed: 34047487
J Clin Oncol. 2018 Jul 20;36(21):2181-2189
pubmed: 29874137
J Int Neuropsychol Soc. 2013 Jan;19(1):44-53
pubmed: 23095276
Cancer Nurs. 2014 Nov-Dec;37(6):E1-E14
pubmed: 24633333
J Clin Oncol. 2004 Feb 15;22(4):706-13
pubmed: 14966095
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Paediatr Neurol. 2010 Mar;14(2):106-15
pubmed: 19931477
Qual Life Res. 2013 Feb;22(1):185-201
pubmed: 22392522
Cancer Med. 2022 Jan;11(1):245-256
pubmed: 34800006
Lancet Child Adolesc Health. 2021 Nov;5(11):814-824
pubmed: 34624241
Br J Cancer. 2010 Feb 2;102(3):620-6
pubmed: 20051948
Pediatr Blood Cancer. 2013 Aug;60(8):1350-7
pubmed: 23444345
Neuropsychology. 2009 Nov;23(6):705-17
pubmed: 19899829
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Cancer. 2003 May 15;97(10):2512-9
pubmed: 12733151
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Radiother Oncol. 2017 Jul;124(1):89-97
pubmed: 28655455
Curr Probl Cancer. 2003 Jul-Aug;27(4):177-97
pubmed: 12855950
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
pubmed: 20171513
J Clin Oncol. 2017 Sep 20;35(27):3169-3171
pubmed: 28644775
Childs Nerv Syst. 1991 Feb;7(1):2-12
pubmed: 2054802
Lancet Oncol. 2011 Jul;12(7):703-8
pubmed: 21354373
Front Psychol. 2018 Apr 23;9:582
pubmed: 29740370